BPC-157 + TB-500 + GHK-Cu

A combined peptide preparation studied in dermal and cellular research.

Molecular Profile

Type
Peptide blend

Components

GHK-Cu

Molecular formula
C14H24CuN6O4
Molecular weight
~403.9 g/mol
CAS number
89030-95-5
Sequence
Gly-His-Lys + Cu(II)

TB-500 (Ac-LKKTETQ fragment)

Molecular formula
C39H67N9O13
Molecular weight
~878 g/mol
CAS number
885340-08-9
Sequence
Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln

BPC-157

Molecular formula
C62H98N16O22
Molecular weight
1,419.5 g/mol
CAS number
137525-51-0
Sequence
GEPPPGKPADDAGLV

Mechanism & Target Class

A three-component blend of a copper-binding tripeptide (GHK-Cu), a Thymosin Beta-4 fragment (TB-500) and a gastric pentadecapeptide (BPC-157). Each component has a distinct structure and target class; no combined descriptor exists.

Storage & Handling

Lyophilized
-20°C, sealed, protected from light/moisture.
Handling
Avoid freeze-thaw; protect from light; component stabilities differ.

References (26)

  1. Reviews

    1

    Pickart L (2008). J Biomater Sci Polym Ed

    DOI: 10.1163/156856208784909435PubMed 18644225

  2. 2

    Pickart L, et al. (2015). Biomed Res Int

    DOI: 10.1155/2015/648108PubMed 26236730

  3. 3

    Dou Y, et al. (2020). Aging Pathobiol Ther

    DOI: 10.31491/apt.2020.03.014PubMed 35083444

  4. 4

    Bubb MR (2003). Vitam Horm

    DOI: 10.1016/s0083-6729(03)01008-2PubMed 12852258

  5. 5

    Kleinman HK, Sosne G (2016). Vitam Horm

    DOI: 10.1016/bs.vh.2016.04.005PubMed 27450738

  6. 6

    Yang WS, et al. (2019). Eur J Dermatol

    DOI: 10.1684/ejd.2019.3642PubMed 31649007

  7. 7

    Seiwerth S, et al. (2018). Curr Pharm Des

    DOI: 10.2174/1381612824666180712110447PubMed 29998800

  8. 8

    Seiwerth S, et al. (2021). Front Pharmacol

    DOI: 10.3389/fphar.2021.627533PubMed 34267654

  9. Primary research

    9

    Maquart FX, et al. (1988). FEBS Lett

    DOI: 10.1016/0014-5793(88)80509-xPubMed 3169264

  10. 10

    Wegrowski Y, et al. (1992). Life Sci

    DOI: 10.1016/0024-3205(92)90504-iPubMed 1522753

  11. 11

    Siméon A, et al. (2000). Life Sci

    DOI: 10.1016/s0024-3205(00)00803-1PubMed 11045606

  12. 12

    Choi HR, et al. (2012). J Pept Sci

    DOI: 10.1002/psc.2455PubMed 23019153

  13. 13

    Gruchlik A, et al. (2012). Acta Pol Pharm

    PubMed 23285694

  14. 14

    Jiang F, et al. (2023). J Cosmet Dermatol

    DOI: 10.1111/jocd.15763PubMed 37062921

  15. 15

    Malinda KM, et al. (1999). J Invest Dermatol

    DOI: 10.1046/j.1523-1747.1999.00708.xPubMed 10469335

  16. 16

    Philp D, et al. (2003). FASEB J

    DOI: 10.1096/fj.03-0121fjePubMed 14500546

  17. 17

    Philp D, et al. (2006). J Cell Physiol

    DOI: 10.1002/jcp.20650PubMed 16607611

  18. 18

    Philp D, et al. (2003). Wound Repair Regen

    DOI: 10.1046/j.1524-475x.2003.11105.xPubMed 12581423

  19. 19

    Treadwell T, et al. (2012). Ann N Y Acad Sci

    DOI: 10.1111/j.1749-6632.2012.06717.xPubMed 23050815

  20. 20

    Seiwerth S, et al. (1997). J Physiol Paris

    DOI: 10.1016/s0928-4257(97)89480-6PubMed 9403790

  21. 21

    Mikus D, et al. (2001). Burns

    DOI: 10.1016/s0305-4179(01)00055-9PubMed 11718984

  22. 22

    Chang CH, et al. (2011). J Appl Physiol

    DOI: 10.1152/japplphysiol.00945.2010PubMed 21030672

  23. 23

    Chang CH, et al. (2014). Molecules

    DOI: 10.3390/molecules191119066PubMed 25415472

  24. 24

    Skorjanec S, et al. (2009). Dig Dis Sci

    DOI: 10.1007/s10620-008-0332-9PubMed 18649140

  25. 25

    Pickart L, Margolina A (2018). Int J Mol Sci

    DOI: 10.3390/ijms19071987

  26. 26

    Esposito S, et al. (2012). Drug Test Anal

    DOI: 10.1002/dta.1402